NATCO Pharma Ltd

NATCO Pharma Ltd was incorporated in Hyderabad in 1981.It is a vertically integrated and R&D focused pharmaceutical company engaged in developing manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company’s focus is primarily on niche therapeutic areas and complex products. Company has its business in over 40 countries, some of these are through our subsidiaries such as NATCOFARMA DO BRASIL, NATCO PHARMA CANADA and NATCO Pharma Australia PTY Ltd.NATCO currently consists of more than 2,500 employees and is consistently ranked among the fastest growing pharmaceutical companies in India.  NATCO has at present, 90 Indian and 160 international granted patents. Furthermore, it has filed for 221 Indian and 239 international applications. NATCO Pharma Limited has initiated Phase-III clinical trial of Molnupiravir capsules in India. Phase-III clinical trial is initiated to evaluate the efficacy and safety of MolnupiravirCapsules in mild COVID-19 patients. NATCO’s clinical trial is planned in 32 hospitals across India.As a responsible corporate citizen, NATCO Pharma, has 14 lakh tablets of Barinat 4mg to the Telangana government through NATCO Trust.Their shareholding pattern include: Promoters having 48.87% shares, FIIs having 16.34% shares, DIIs having 16.15% shares and Public having 18.65% shares.For the quarter ended 31-03-2021, the company has reported a Consolidated Total Income of Rs 359.7 Crore, down 6.81% from last quarter Total Income of Rs 386 Crore and down 24.62% from last year same quarter Total Income of Rs 477.2 Crore. Company has reported net profit after tax of Rs 53 Crore in latest quarter.